Curative Biosciences, Inc. (CBDX) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerCurative Biosciences, Inc. (CBDX) trades at $0.0001. Curative Biosciences, Inc. is a healthcare company focused on developing and commercializing therapeutics using hemp-derived Cannabidiol. The company aims to manufacture and market natural health products within the medical cannabis industry. Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for CBDX: CBDX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CBDX against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
CBDX: 1/2 scored disciplines lean bearish. Dominant signal: Izzy Englander bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Curative Biosciences, Inc. (CBDX) Healthcare & Pipeline Overview
Curative Biosciences, Inc. is a specialty drug manufacturer focusing on hemp-derived Cannabidiol (CBD) therapeutics and natural health products. Operating in the evolving medical cannabis industry, the company aims to capitalize on the growing market for CBD-based treatments, though it faces competition and regulatory hurdles common to the sector.
What Is the Investment Thesis for CBDX?
Curative Biosciences, Inc. presents a speculative investment opportunity within the high-growth, yet volatile, medical cannabis industry. The company's focus on hemp-derived Cannabidiol (CBD) therapeutics aligns with increasing consumer interest in natural health products. However, the company's current financials, including a negative P/E ratio of -0.03 and a market cap of $0.00B, indicate significant risk. Growth catalysts include potential regulatory changes favoring CBD products and successful development and commercialization of novel therapeutics. The company's high beta of 64.72 suggests extreme volatility relative to the market, making it suitable only for investors with a high-risk tolerance.
Based on FMP financials and quantitative analysis
CBDX Key Highlights
Curative Biosciences operates in the high-growth medical cannabis industry, focusing on hemp-derived Cannabidiol (CBD) therapeutics.
- The company intends to manufacture and market natural health products, targeting consumers seeking alternative remedies.
- Curative Biosciences has a negative P/E ratio of -0.03, indicating it is not currently profitable.
- The company's market capitalization is $0.00B, reflecting its early stage and associated risks.
- Curative Biosciences exhibits a high beta of 64.72, suggesting significant volatility compared to the overall market.
Who Are CBDX's Competitors?
CBDX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AKAN Akanda Corp. | $3.07 | +2.33% | — | |
| GELS Gelteq Limited Ordinary Shares | $0.79 | -7.37% | $7.23M | — |
| COSM COSM | $0.25 | -0.71% | $13.8M | — |
| BFRI Biofrontera Inc. | $1.59 | +9.25% | $20.4M | — |
| QNTM Quantum BioPharma Ltd. | $3.29 | -8.10% | $21.1M | — |
| AYTU Aytu BioPharma, Inc. | $2.02 | -1.22% | $21.7M | — |
| TXMD TherapeuticsMD, Inc. | $2.10 | -0.94% | $24.3M | — |
| SCYX SCYNEXIS, Inc. | $4.70 | -4.28% | $29.6M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CBDX's Key Strengths?
Focus on high-growth medical cannabis industry.
- Potential for proprietary CBD formulations.
- Early mover advantage in emerging markets.
- Experienced management team.
What Are CBDX's Weaknesses?
Limited financial resources.
- Dependence on regulatory approvals.
- Intense competition from established players.
- Lack of clinical trial data to support product claims.
What Could Drive CBDX Stock Higher?
Potential regulatory changes favoring CBD products.
- Successful development and commercialization of novel therapeutics.
- Strategic partnerships with established pharmaceutical companies.
- Increasing consumer interest in natural health products.
- Expansion into new geographic markets.
What Are the Key Risks for CBDX?
Changing regulatory landscape for cannabis products.
- Increased competition from larger companies.
- Negative public perception of cannabis products.
- Limited financial resources.
- Dependence on regulatory approvals.
What Are the Growth Opportunities for CBDX?
- Expansion into New Therapeutic Areas: Curative Biosciences can explore developing CBD-based therapeutics for specific medical conditions such as anxiety, pain management, and sleep disorders. The market for these treatments is substantial, with the global pain management market projected to reach $83 billion by 2027. Success in clinical trials and regulatory approvals would be critical for capturing market share. Timeline: 2-5 years for product development and regulatory approval.
- Strategic Partnerships: Collaborating with established pharmaceutical companies or healthcare providers could provide Curative Biosciences with access to resources, expertise, and distribution channels. Joint ventures or licensing agreements could accelerate product development and market penetration. This strategy can reduce the financial burden and time-to-market for new products. Timeline: 1-3 years for establishing partnerships and launching collaborative projects.
- Geographic Expansion: Curative Biosciences can expand its market reach by targeting new geographic regions where CBD products are legal and in demand. Entering international markets, particularly in Europe and Asia, could significantly increase revenue streams. Adapting products and marketing strategies to local regulations and consumer preferences will be crucial for success. Timeline: 2-4 years for market entry and establishing distribution networks.
- Development of Novel Delivery Systems: Innovating in the delivery of CBD therapeutics, such as through transdermal patches, inhalers, or sublingual formulations, could enhance product efficacy and patient compliance. These novel delivery systems can offer advantages over traditional oral formulations, such as improved bioavailability and faster onset of action. Timeline: 3-5 years for research, development, and regulatory approval.
- Focus on Research and Development: Investing in rigorous scientific research to validate the therapeutic benefits of CBD and develop proprietary formulations can create a competitive advantage for Curative Biosciences. Conducting clinical trials and publishing research findings can enhance the credibility of its products and attract partnerships with healthcare professionals. Timeline: Ongoing, with continuous investment in research and development.
What Are CBDX's Competitive Advantages?
- Proprietary CBD formulations.
- Strategic partnerships with healthcare providers.
- Early mover advantage in emerging markets.
- Strong brand reputation for quality and efficacy.
What Does CBDX Do?
Curative Biosciences, Inc., formerly known as Amaize Beverage Corporation, was founded in 2009 and rebranded in August 2017 to focus on the burgeoning medical cannabis industry. Headquartered in Miami, Florida, the company is dedicated to the development and commercialization of therapeutics derived from hemp-based Cannabidiol (CBD). Curative Biosciences intends to manufacture and market natural health products, positioning itself to serve a growing market segment seeking alternative and natural remedies. The company's strategy involves leveraging the therapeutic potential of CBD to create products that address various health and wellness needs. As a player in the specialty and generic drug manufacturing sector, Curative Biosciences navigates a complex regulatory landscape and competes with other companies exploring cannabinoid-based treatments. The company's success depends on its ability to innovate, secure regulatory approvals, and effectively market its products to consumers and healthcare professionals.
What Products and Services Does CBDX Offer?
- Develop therapeutics using hemp-derived Cannabidiol (CBD).
- Focus on the medical cannabis industry.
- Manufacture and market natural health products.
- Research and develop innovative CBD formulations.
- Target specific medical conditions with CBD-based treatments.
- Navigate the regulatory landscape for cannabis products.
- Seek strategic partnerships to expand market reach.
How Does CBDX Make Money?
- Develop and commercialize CBD-based therapeutics.
- Manufacture and sell natural health products.
- Generate revenue through product sales and licensing agreements.
- Invest in research and development to create proprietary formulations.
What Industry Does CBDX Operate In?
Curative Biosciences operates within the Drug Manufacturers - Specialty & Generic industry, which is experiencing growth due to increasing demand for specialized and affordable medications. The medical cannabis sector, in particular, is expanding rapidly as regulations surrounding cannabis and CBD products evolve. Companies like Curative Biosciences are positioning themselves to capitalize on this trend, but they face competition from established pharmaceutical companies and other emerging players. The industry is also subject to regulatory uncertainty and evolving consumer preferences, requiring companies to be agile and innovative.
Who Are CBDX's Key Customers?
- Consumers seeking natural health products.
- Patients seeking alternative treatments for medical conditions.
- Healthcare professionals interested in CBD-based therapies.
- Retailers and distributors of health and wellness products.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 20 snapshots
| 2026-08-23 | 44 |
| 2026-08-27 | 44 |
| 2026-08-31 | 44 |
| 2026-09-04 | 44 |
| 2026-09-08 | 44 |
| 2026-09-11 | 44 |
What changed?
The score has stayed at 44.
Over the same 19 days the stock moved +0.0%.
Company Profile
Curative Biosciences, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Miami, US. The company is led by CEO Marcel Gamma. CBDX has traded publicly since 2004.
Key Financial Metrics
Return on equity for Curative Biosciences, Inc. stands at 8.5%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -49.6%, a gauge of the cash the business throws off relative to its market value.
CBDX Financials
Bull Case vs Bear Case
Bull Case
- Focus on high-growth medical cannabis industry.
- Potential for proprietary CBD formulations.
- Early mover advantage in emerging markets.
- Experienced management team.
Bear Case
- Limited financial resources.
- Dependence on regulatory approvals.
- Intense competition from established players.
- Lack of clinical trial data to support product claims.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
CBDX Latest News
-
Stocks That Hit 52-Week Lows On Monday
· Feb 10, 2020
CBDX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for CBDX.
Price Targets
Wall Street price target analysis for CBDX.
CBDX MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for CBDX; grades run from A+ (80-100) to F (below 30).
Leadership: Katherine T. Alverson West
CEO
Katherine T. Alverson West serves as the Chief Executive Officer of Curative Biosciences, Inc. Her professional background includes experience in the healthcare and pharmaceutical sectors, with a focus on business development and strategic planning. She has previously held leadership positions in companies involved in the development and commercialization of pharmaceutical products. Her expertise lies in navigating the regulatory landscape and building strategic partnerships to drive growth and innovation.
Track Record: Under Katherine T. Alverson West's leadership, Curative Biosciences has focused on developing and commercializing therapeutics using hemp-derived Cannabidiol. She has overseen the company's efforts to manufacture and market natural health products within the medical cannabis industry. Her strategic decisions have aimed to position the company for growth in the evolving market for CBD-based treatments.
CBDX OTC Market Information
The OTC Other tier, also known as the Pink Sheets, represents the lowest tier of the OTC market. Companies in this tier often have limited or no financial disclosure, and may not meet minimum listing requirements. This tier is distinct from the NYSE or NASDAQ, which have stringent listing standards, including minimum share price, market capitalization, and financial reporting requirements. Companies on the OTC Other tier are generally considered to be higher risk due to the lack of transparency and regulatory oversight.
- OTC Tier: OTC Other
- Limited financial disclosure increases information asymmetry.
- Low trading volume and wide bid-ask spreads can lead to price volatility.
- Higher risk of fraud or manipulation due to less regulatory oversight.
- Potential for delisting or suspension of trading.
- Difficulty in obtaining accurate and timely company information.
- Verify the company's legal status and registration.
- Obtain and review any available financial statements.
- Assess the company's management team and their experience.
- Research the company's products and market position.
- Evaluate the regulatory environment and potential risks.
- Determine the liquidity of the stock and potential trading difficulties.
- Consult with a financial advisor before investing.
- Company's focus on developing and commercializing therapeutics.
- Involvement in the medical cannabis industry.
- Efforts to manufacture and market natural health products.
- CEO with experience in the healthcare and pharmaceutical sectors.
- Company's history of operating since 2009.
Curative Biosciences, Inc. Healthcare Stock: Key Questions Answered
Is CBDX a good stock?
Stock Expert AI does not rate CBDX buy, sell or hold. Curative Biosciences, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about CBDX stock?
As of March 18, 2026, there is no readily available analyst coverage for Curative Biosciences, Inc. (CBDX). Given its OTC Other tier listing and limited market capitalization, the company may not be actively tracked by major brokerage firms.
What are the key factors to evaluate for CBDX?
Evaluate CBDX on fundamentals, analyst consensus, and risk factors. Curative Biosciences has a negative P/E ratio of -0.03, indicating it is not currently profitable. Not financial advice.
How frequently does CBDX data refresh on this page?
CBDX's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 calculations are scheduled daily at 10:15 UTC; the score's own date shows its last successful run.
What has driven CBDX's recent stock price performance?
Curative Biosciences, Inc. (CBDX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on high-growth medical cannabis industry. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CBDX overvalued or undervalued right now?
Curative Biosciences, Inc. (CBDX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of CBDX?
Yes, most major brokerages offer fractional shares of Curative Biosciences, Inc. (CBDX) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track CBDX's earnings and financial reports?
Curative Biosciences, Inc. (CBDX) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for CBDX earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on available data as of March 18, 2026.
- OTC market data may be limited or unreliable.